Ann: Change of Registered Office and Principal Place of Business, page-11

As I have said before at 6 mins in the interview:

After a heart attack or stroke there is damage to the heart. Drugs out there at the moment being developed try to minimise the brain injury, but weeks and months after a stroke or heart attack patients will suffer some sort of risk associated with developing heart failure. NYR-BO3 is the only drug in the world that reduces that risk. There is no point of saving someone and them dying months later from another occurrence. Having a drug that does all three things changes everything for hospitals and first point of care

This drug is a game changer and come safety clearence this is well on its way to become a multi billion dollar drug. To say this is a 19 million market cap, a penny valuation is a joke. But that will change shortly